At a time when Chinese government is coming down heavily on polluting active pharma ingredients (API) units, the Indian bulk drug industry is doubling down efforts to get more recognition from the ...
Teva (NYSE:TEVA) plans to divest its active-pharmaceutical ingredient (API) business as part of its Pivot to Growth strategy to focus on its core business strengths. "The intent to divest TAPI will ...
Reducing its import dependence, one innovation at a time, Gujarat's pharmaceutical landscape is soon to change and evolve. With some 115 new plants getting manufacturing licences for making bulk drugs ...
The drug firm is shutting down the unit because of the low demand for the product in the export markets AstraZeneca Pharma India will close its Active Pharmaceutical Ingredient (API) unit at Bengaluru ...
Monday's announcement will see Dr. Reddy's API facility in Hyderabad sold to Therapiva Pvt. Ltd, a JV between a subsidiary of Neopharma Llc (parent of Neopharma Inc.) and Laxai Life Sciences. Photo: ...
The Department of Pharmaceuticals (DoP) has issued revised Guidelines for the production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical key starting materials (KSMs) ...
Sigachi Industries acquired 80 per cent stake in API manufacturing company, Trimax Bio Sciences, Raichur, Karnataka. “The board has approved the acquisition of 2.88 crore equity shares of ₹10 each ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results